Cipla Limited
CIPLA
Rangering i aksjer
#1804
Cipla Limited, along with its associated entities, operates as a global... Cipla Limited, along with its associated entities, operates as a global pharmaceutical enterprise, specializing in the creation and distribution of a wide array of medicinal products. Its extensive portfolio includes both active pharmaceutical ingredients (APIs) and a diverse range of finished formulations, addressing numerous therapeutic areas such as cardiovascular diseases, metabolic disorders, HIV, respiratory conditions, urology, oncology, pediatric health, infectious diseases, critical care, hepatitis, women's health, ophthalmology, and neuropsychiatry. The company maintains a strong focus on respiratory treatments, offering various inhalers, nasal sprays, injectables, and biosimilars. Cipla has also forged significant partnerships, including a licensing arrangement with Merck & Co., Inc. for the manufacturing and commercialization of the investigational oral antiviral drug Molnupiravir, and a separate license agreement with Eli Lilly and Company for baricitinib, indicated for COVID-19. Furthermore, it collaborates with Dr. Reddy's Laboratories Ltd, Sun Pharmaceutical Industries Limited, Emcure Pharmaceuticals Limited, and Torrent Pharmaceuticals Limited for Molnupiravir's clinical trials. Established in 1935, Cipla's corporate headquarters are located in Mumbai, India.
Aksjekurs
$14.64
Markedsverdi
$11.83B
Endring (1 dag)
0.10%
Endring (1 år)
-18.29%
Land
IN
Handel Cipla Limited (CIPLA)
Kategori
Healthcare
EPS for Cipla Limited (CIPLA)
EPS per June 2026 TTM: $0.46
Ifølge de siste økonomiske rapportene og aksjekursen til Cipla Limited er selskapets nåværende EPS (TTM) $0.46. Ved slutten av 2024 hadde selskapet en EPS på $0.61, en økning sammenlignet med EPS-en i 2023 som var $0.42.
EPS-historikk for Cipla Limited fra 2004 til 2026
EPS ved slutten av hvert år
| År | EPS | Endre |
|---|---|---|
| 2026 (TTM) | $0.46 | -39.39% |
| 2025 | $0.76 | 24.70% |
| 2024 | $0.61 | 44.90% |
| 2023 | $0.42 | 2.80% |
| 2022 | $0.41 | 0.88% |
| 2021 | $0.41 | 59.95% |
| 2020 | $0.25 | -6.77% |
| 2019 | $0.27 | 1.49% |
| 2018 | $0.27 | 39.41% |
| 2017 | $0.19 | -24.42% |
| 2016 | $0.26 | 8.40% |
| 2015 | $0.24 | -18.30% |
| 2014 | $0.29 | -18.53% |
| 2013 | $0.35 | 26.01% |
| 2012 | $0.28 | 1.66% |
| 2011 | $0.28 | -9.38% |
| 2010 | $0.31 | 56.09% |
| 2009 | $0.20 | -13.31% |
| 2008 | $0.23 | 13.49% |
| 2007 | $0.20 | 9.18% |
| 2006 | $0.18 | 45.52% |
| 2005 | $0.13 | 37.67% |
| 2004 | $0.09 | 0.00% |
EPS for lignende selskaper eller konkurrenter
| Selskap | EPS | EPS-forskjell | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $0.56 | 20.78% |
IN
|
